Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $132.29M.
ENTERPRISE VALUE (EV)
$132.29M
NervGen Pharma Corp. Common stock
Market Cap
$148.36M
Enterprise Value (EV)
$132.29M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $148.36M | $132.29M |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | $128.84M |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.15M | $121.28M |
| Anavex Life Sciences Corp. (AVXL)vs › | $149.34M | $31.01M |
| Codexis, Inc. (CDXS)vs › | $151.12M | $196.54M |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | $133.29M |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.89M | $143.50M |
| Immuneering Corporation (IMRX)vs › | $144.66M | $106.97M |
| ALX Oncology Holdings Inc. (ALXO)vs › | $153.40M | $140.42M |
| Nyxoah S.A. (NYXH)vs › | $143.10M | $129.92M |
Market Cap
$148.36M
Total Debt
$0.00
Cash
$16.07M
Enterprise Value
$132.29M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
